Drugs / ALDP001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07219849 | Oct 2025 → Apr 2026 overdue | seasonal allergic rhinitis | Alixer Nexgen Therapeutics Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALDP 001 | “A Two-part Adaptive Double-blind Randomized Placebo-controlled Study to Assess the Appropriate Dose and the Appropriate Dosing Frequency of ALDP 001 in Adults With Seasonal...” NCT07219849 ↗ |
| Route | Intranasal | “ALDP001 Nasal Spray” NCT07219849 ↗ |